GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It

2Firsts Events by 2FIRSTS Charlotte, edited by Sophia Lv
May.30.2024
GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

 

The forum began with a welcome address from GTNF founder and Executive Director of the GTNF Trust Fund, Elise Rasmussen. In her speech, Rasmussen highlighted the uncertainty in global nicotine regulation, emphasizing the volatile tobacco policies in the UK and US since the end of last year. She also expressed gratitude to the experts sharing their insights at the forum.

 

Dispelling Nicotine Myths: A "Horror" Narrative Around E-Cigarettes

 

The first keynote speech was delivered by Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School. His presentation focused on the pathological characteristics of nicotine and synthetic nicotine, detailing the molecular structure, receptors, and anatomical absorption process in the human body.

 

Professor Strupp reiterated his key point that nicotine, as a molecular structure, is not carcinogenic. He vividly compared e-cigarettes to traditional combustible cigarettes using the analogy of electric cars versus fuel cars, highlighting that the underlying logic of e-cigarettes is similar to the advantages of electric cars, which are "a cleaner process and less damage."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School

 

Following Professor Strupp's speech, James Murphy, Director of Research and Science at British American Tobacco (BAT), delivered the second keynote speech. Murphy, who previously led BAT's Group of Reduced Risk Products (PRRP) Science and was the product manager for the Americas and Sub-Saharan Africa regions, drew from his experiences in developing markets to argue that the public health community needs to adopt a consistent scientific viewpoint on new-generation tobacco products to provide regulators worldwide with accurate information and create a "stable framework."

 

In his keynote, Murphy shared his experiences and stated that the dual themes of the forum have dual significance in "promoting public health" and "focusing on social welfare."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
James Murphy, Director of Research and Science at British American Tobacco (BAT)

 

Deepening the Discussion on Nicotine and E-Cigarettes

 

The first panel discussion invited several industry experts to delve deeper into misunderstandings and myths about nicotine and e-cigarettes. The discussion was moderated by Jasjit Ahluwalia, Professor of Behavioral and Social Sciences and Professor of Medicine at Brown University School of Public Health and Alpert Medical School. The panelists included Delon Human, family doctor and president of the "Health Diplomats" group, Dave Dobbins, former COO of the American Legacy Foundation/Truth Initiative, and Sudhanshu Patwardhan, nicotine expert and health technology entrepreneur.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The first panel discussion deepened the discussion on misunderstandings and myths about nicotine and e-cigarettes

 

Ahluwalia noted that over the past decade, as the e-cigarette market has grown, the idea that "e-cigarettes are more harmful than traditional combustible cigarettes" has gained traction among smokers, leading many who had switched to e-cigarettes to return to smoking. He described this as "incredible"; the panelists agreed that the industry should invest more resources in related research to combat the "horror narrative" with science.

 

Dobbins, from a market perspective, discussed the proper direction for regulating nicotine products from the standpoint of human rights and legal principles. He argued that every adult's actions and choices are their own responsibility, and thus "adults need to be treated as adults, not managed with flavor bans or outright prohibitions on nicotine intake methods."

 

Nicotine from an Agricultural Perspective: Ensuring Farmers' Interests

 

The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers, an area less frequently highlighted by the industry. The session included George Cassels-Smith, CEO of a tobacco technology company, Ramsey S. Lewis, Professor of Plant Breeding at North Carolina State University, Carlos Pulcinelli, Global Project Manager at Alliance One International, and Lea Scott, Senior Vice President of Universal Leaf Tobacco Co.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers

 

During the discussion, the panelists analyzed the development of upstream tobacco farming from the perspectives of tobacco farmers, buyers, and regulators across the supply chain. They emphasized the critical importance of tobacco leaf quality for all stakeholders. Professor Lewis highlighted the success of developing high-quality, high-yield, disease-resistant tobacco varieties through genetic modification over the past decade. He suggested that future research and development to increase the added value of raw tobacco leaves would be a significant focus for the industry.

 

The panelists unanimously agreed that not everyone realizes that nicotine, like large-scale agriculture in livestock and crops, involves a "farm-to-table" process. Ensuring the interests of farmers who grow tobacco is essential to meet the increasing ESG (Environmental, Social, and Governance) requirements from regulators and society for nicotine companies.

 

 

About GTNF InFocus


 

InFocus is the largest online tobacco and nicotine conference. Bringing together thought leaders, industry voices, and leaf and public health experts。
 

2FIRSTS focused on the core topics and significant viewpoints of the forum, conducting in-depth interviews with government officials, business executives, and industry experts from various countries. We published over 20 high-quality reports in both text and video formats.

This series of reports not only promoted GTNF's global reach but also provided valuable information and profound insights for the high-quality development of the e-cigarette industry.

Here is an overview of key content covered by 2FIRSTS at GTNF 2023:

1. FDA CTP Director Brian King: Submitting PMTA is No Equivalent to Legal Sale
 https://www.2firsts.com/news/fda-director-brian-king-on-e-cigarette-compliance-and-tracking-systems

2. GTNF 2023: Sustainable Development and New Vape Products
https://www.2firsts.com/news/the-future-of-e-cigarettes-sustainable-development-and-new-products

3. GTNF Discusses Addressing Youth Misuse of Harm Reduction Products: A Collaborative Effort Needed
 https://www.2firsts.com/news/gtnf-discusses-addressing-youth-misuse-of-harm-reduction-products-a-collaborative-effort-needed

4. Interview with GTNF Founder: Transform Industry Through Unique Dialogues
https://www.2firsts.com/news/interview-with-gtnf-founder-transform-industry-through-unique-dialogues

Moving forward, 2FIRSTS will continue to closely track the latest developments and trends in the e-cigarette industry, committed to providing readers with cutting-edge information and in-depth analysis. This ensures that readers receive accurate and comprehensive first-hand industry updates promptly.

 

STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
HM Revenue & Customs (HMRC) has released sample images of the UK’s transitional vaping duty stamps, showing red and yellow versions ahead of the new Vaping Products Duty and Vaping Duty Stamps Scheme starting on October 1, 2026. Transitional stamps contain physical security features but no digital scanning function. Approved businesses may purchase them through November 30 and affix them through December 31. HMRC has not stated that the red and yellow samples represent different product categories or tax statuses.
Regulations
Sep.02
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22